Phosphate-Binding Agents has 7 known drug interactions based on U.S. FDA drug labeling data. Of these, 1 are contraindicated combinations that should be avoided entirely. Notable interactions include combinations with Burosumab, Calcitriol, Calcitriol Capsules 0.25 Mcg. Patients taking Phosphate-Binding Agents should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 7
- Contraindicated
- 1
- Moderate
- 6
Contraindicated (1)
- Phosphate-Binding Agents + Burosumab— Concomitant use increases phosphate concentrations greater than expected, potentially resulting in hyperphosphatemia and…
Moderate (6)
- Phosphate-Binding Agents + Calcitriol— Dosage adjustment required as calcitriol affects phosphate transport; dosing must be adjusted based on serum phosphate l…
- Phosphate-Binding Agents + Calcitriol Capsules 0.25 Mcg— Dosage of phosphate-binding agents must be adjusted based on serum phosphate concentration due to calcitriol's effect on…
- Phosphate-Binding Agents + Cholestyramine Light— Cholestyramine interferes with absorption of oral phosphate supplements.
- Phosphate-Binding Agents + Cholestyramine Powder For Suspension— Cholestyramine may interfere with absorption of oral phosphate supplements.
- Phosphate-Binding Agents + Choleystyramine Light— Cholestyramine may interfere with the absorption of oral phosphate supplements.
- Phosphate-Binding Agents + Colestipol Hydrochloride— Bile acid binding resins may interfere with the absorption of oral phosphate supplements.